GenScript Debuts Industry's Highest Throughput DNA Synthesis Platform for Commercial DNA Digital Data Storage

Each CMOS DNA chip carries 8.4 million unique oligos

OAKLAND, Calif. and PISCATAWAY, N.J., April 13, 2022 /PRNewswire/ -- GenScript USA Inc., the world's leading life science research tools and services provider, announced today the debut of the highest throughput semiconductor chip for DNA synthesis in the industry at the annual Built With Biology global conference. Developed using GenScript's proprietary miniature semiconductor chip technology, the High-Density DNA Synthesis Chip allows the synthesis of 8.4 million unique oligos simultaneously, up to 170 bases per oligo. It is first commercial platform for DNA digital data storage.

GenScript's next-generation DNA synthesis platform carries four chips, and more than 5.7 billion oligos may be synthesized in one run. Researchers encoded 100 Mb of mixed data types in the DNA to test the High-Density DNA Synthesis Chip's storage utility and retrieved 100% of the encoded data with no loss.

"DNA could be a powerful medium for data storage given its theoretically limitless storage capacity, stability, and minimal maintenance requirements," said Cedric Wu, Ph.D., vice president of GenScript's Innovation Center. "However, our inability to quickly generate large numbers of DNA sequences to store new material has hindered its commercial promise. GenScript's semiconductor technology addresses DNA digital data storage's most vexing challenges. It is turning fiction into reality."

The size of the global DataSphere is predicted to hit 160 trillion gigabytes by 2025, and the capacity to store it is running out. Storing data in large server farms is unsustainable in the long term, as it requires too much energy, land, maintenance, and money.

GenScript's High-Density DNA Synthesis Chip's active electrode field has a density of over 2.5 million sites per square centimeter. Each electrode site on the chip is independently controlled and can produce a different high-fidelity oligo sequence at every location. GenScript's scientists have built robust pipelines and algorithms for quicker data encoding and decoding along with advanced error correction.

Dr. Wu will share details on the platform and the company's preliminary DNA data storage results at a fireside chat today at 11:20 a.m. at the annual Built With Biology Conference. GenScript is actively seeking participants for a partnership program to expand the applicability of the data storage platform.

In addition to DNA digital data storage, GenScript will be expanding the development of the High-Density DNA Synthesis Chip platform to enhanced targeted enrichment sequencing, precision mutant antibody/enzyme libraries, spatial genomics, and digital microfluidics. It is expected to be fully commercially available in the second half of 2022.

About GenScript Biotech Corporation

GenScript Biotech Corporation (Stock Code: 1548.HK) is a global biotechnology group. Based on its leading gene synthesis technology, GenScript has developed four major platforms including the global cell therapy platform, the biologics contract development and manufacturing organization (CDMO) platform, the contract research organization (CRO) platform and the industrial synthesis product platform.

GenScript was founded in New Jersey, US in 2002 and listed on the Hong Kong Stock Exchange in 2015. GenScript's business operation spans over 100 countries and regions worldwide, with legal entities located in the U.S., Mainland China, Hong Kong, Japan, Singapore, Netherlands and Ireland. GenScript has provided premium, convenient, and reliable products and services for over 100,000 customers.

GenScript has a number of intellectual property rights and technical secrets, including more than 100 patents and over 270 patent applications. As of December 31-st, 2020, GenScript's products and services have been cited by 52,500 peer-reviewed journal articles worldwide.

For more information visit www.genscript.com.

CONTACTS

For GenScript

Cedric Wu, Ph.D.
Vice President
[email protected]  

For Media

Susan Thomas
Principal, Endpoint Communications
(619) 540-9195
[email protected]

SOURCE GenScript

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED